3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
36
Neoplasms
8
HER2-positive Breast Cancer
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Salivary Gland Neoplasms
2
Pathologic Complete Response
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Liver Neoplasms
1
Hemangiosarcoma
1
Heart Failure
1
Interventions
atezolizumab
3
fludarabine
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Pemetrexed
2
Nivolumab
2
Cisplatin
2
spartalizumab
1
repotrectinib
1
pertuzumab
1
lutetium Lu 177 dotatate
1
gilteritinib
1
enzalutamide
1
durvalumab
1
copper dotatate CU-64
1
cemiplimab
1
Trastuzumab
1
Sodium Chloride
1
Radiotherapy
1
Radiosurgery
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Injections
1
Idarubicin
1
HuMax-IL8
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Histologic Type
×
pertuzumab
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled